## **Core Concept**
The question targets the pharmacological management of moderate-to-severe psoriasis, focusing on the mechanism of action of specific drugs that inhibit interleukins (IL) involved in the disease process. Psoriasis is a chronic inflammatory skin condition characterized by an abnormal immune response, involving T cells and the production of various cytokines, including IL-12 and IL-23. These cytokines play critical roles in the differentiation of T helper cells and the promotion of inflammation.

## **Why the Correct Answer is Right**
Ustekinumab is a monoclonal antibody that targets the p40 subunit of both IL-12 and IL-23, thereby inhibiting their actions. By blocking these cytokines, ustekinumab reduces inflammation and slows down skin cell production, which are key aspects of psoriasis pathology. IL-12 and IL-23 are crucial in the pathogenesis of psoriasis as they are involved in the differentiation and expansion of Th1 and Th17 cells, respectively, which contribute to the inflammatory process.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Etanercept is a TNF-alpha inhibitor used in the treatment of psoriasis, rheumatoid arthritis, and other inflammatory conditions. It does not specifically target IL-12 and IL-23 but rather works by blocking tumor necrosis factor-alpha (TNF-alpha), a different cytokine involved in systemic inflammation.
- **Option B:** Infliximab is another TNF-alpha inhibitor, similar to etanercept, used for treating psoriasis among other conditions. It does not inhibit IL-12 and IL-23 but works by binding to TNF-alpha, preventing it from interacting with its cell surface receptor.
- **Option D:** Secukinumab is an IL-17A inhibitor, which is also effective in treating moderate-to-severe psoriasis. While it targets a cytokine involved in the inflammatory cascade of psoriasis, its mechanism is specific to IL-17A and does not involve the inhibition of IL-12 and IL-23.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that ustekinumab's unique mechanism of action against both IL-12 and IL-23 makes it effective for treating moderate-to-severe psoriasis. This dual inhibition can be particularly beneficial in managing the complex immune dysregulation seen in psoriasis. Ustekinumab is administered via subcutaneous injection and has a significant impact on reducing Psoriasis Area and Severity Index (PASI) scores in patients.

## **Correct Answer:** . Ustekinumab.